118 related articles for article (PubMed ID: 19971022)
1. Response of the Gastrointestinal Tract of the Mouse to 5-Fluorouracil.
Muggia AL; Wagman E; Milles SS; Spiro HM
Am J Pathol; 1963 Apr; 42(4):407-14. PubMed ID: 19971022
[No Abstract] [Full Text] [Related]
2. The effect of 5-fluorouracil upon carcinomas of the gastrointestinal tract and related organs.
WEISS AJ; JACKSON L
Am J Gastroenterol; 1961 Feb; 35():138-46. PubMed ID: 13784045
[No Abstract] [Full Text] [Related]
3. Kanglaite injection plus fluorouracil-based chemotherapy on the reduction of adverse effects and improvement of clinical effectiveness in patients with advanced malignant tumors of the digestive tract: A meta-analysis of 20 RCTs following the PRISMA guidelines.
Song Q; Zhang J; Wu Q; Li G; Leung EL
Medicine (Baltimore); 2020 Apr; 99(17):e19480. PubMed ID: 32332600
[TBL] [Abstract][Full Text] [Related]
4. Comparison between DCF (Docetaxel, Cisplatin and 5-Fluorouracil) and modified EOX (Epirubicin, Oxaliplatin and Capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract.
Ilhan-Mutlu A; Preusser M; Schoppmann SF; Asari R; Ba-Ssalamah A; Schwameis K; Pluschnig U; Birner P; Püspök A; Zacherl J; Hejna M
Anticancer Res; 2013 Aug; 33(8):3455-9. PubMed ID: 23898119
[TBL] [Abstract][Full Text] [Related]
5. Plasma diamine oxidase activity is a useful biomarker for evaluating gastrointestinal tract toxicities during chemotherapy with oral fluorouracil anti-cancer drugs in patients with gastric cancer.
Namikawa T; Fukudome I; Kitagawa H; Okabayashi T; Kobayashi M; Hanazaki K
Oncology; 2012; 82(3):147-52. PubMed ID: 22433290
[TBL] [Abstract][Full Text] [Related]
6. An early phase II study of oral S-1, a newly developed 5-fluorouracil derivative for advanced and recurrent gastrointestinal cancers. The S-1 Gastrointestinal Cancer Study Group.
Sugimachi K; Maehara Y; Horikoshi N; Shimada Y; Sakata Y; Mitachi Y; Taguchi T
Oncology; 1999 Oct; 57(3):202-10. PubMed ID: 10545788
[TBL] [Abstract][Full Text] [Related]
7. Indomethacin-5-fluorouracil-methyl ester dry emulsion: a potential oral delivery system for 5-fluorouracil.
Wang J; Hu Y; Li L; Jiang T; Wang S; Mo F
Drug Dev Ind Pharm; 2010 Jun; 36(6):647-56. PubMed ID: 20136491
[TBL] [Abstract][Full Text] [Related]
8. A trial of high-dose 5-fluorouracil with razoxane or adriamycin in the treatment of advanced adenocarcinoma of the gastrointestinal tract.
Smith BJ; Ashford RF; Bakowski M; Hellman K; Newton K; Phillips R; Lambert J; Jones R; Peters N; Evans M
Am J Clin Oncol; 1983 Aug; 6(4):481-4. PubMed ID: 6346856
[TBL] [Abstract][Full Text] [Related]
9. [In vitro effect of 1-hexylcarbamoyl-5-fluorouracil on human cancer cell lines of gastrointestinal tract].
Kataoka M; Akiyama S; Kawasaki S; Sato T; Asai S; Satta T; Takeshima E; Kondo K; Yamauchi M; Ito K
Gan To Kagaku Ryoho; 1993 Nov; 20(14):2251-4. PubMed ID: 8239696
[No Abstract] [Full Text] [Related]
10. CHEMOTHERAPY OF MALIGNANCIES OF THE GASTROINTESTINAL TRACT.
ROCHLIN DB; SMART CR; SILVA A
Am J Surg; 1965 Jan; 109():43-6. PubMed ID: 14248295
[No Abstract] [Full Text] [Related]
11. TREATMENT OF MALIGNANT NEOPLASMS OF THE GASTROINTESTINAL TRACT WITH A COMBINATION OF 5-FLUOROURACIL AND RADIATION: A RANDOMIZED DOUBLE-BLIND STUDY.
CHILDS DS; MOERTEL CG; HOLBROOK MA; REITEMEIER RJ; COLBY MY
Radiology; 1965 May; 84():843-8. PubMed ID: 14282693
[No Abstract] [Full Text] [Related]
12. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
Choi CW; Choi IK; Seo JH; Kim BS; Kim JS; Kim CD; Um SH; Kim JS; Kim YH
Am J Clin Oncol; 2000 Aug; 23(4):425-8. PubMed ID: 10955877
[TBL] [Abstract][Full Text] [Related]
13. Adriamycin, CCNU, and 5-fluorouracil in patients with advanced gastrointestinal cancer.
Cedermark BJ; Gunven P; Hammarberg C
J Surg Oncol; 1983 Feb; 22(2):125-8. PubMed ID: 6296546
[TBL] [Abstract][Full Text] [Related]
14. Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration.
Kajiwara T; Miura K; Ohnuma S; Shimada M; Komura T; Toshima M; Kohyama A; Kudoh K; Haneda S; Musha H; Naitoh T; Shirasaka T; Unno M
Int J Clin Oncol; 2015 Oct; 20(5):913-21. PubMed ID: 25652909
[TBL] [Abstract][Full Text] [Related]
15. [Change in potassium and sodium content in patients with cancer of the gastrointestinal tract during treatment with 5-fluorouracil].
Lichinitser MR; Sudzhan AV
Lab Delo; 1968; 12():748-51. PubMed ID: 4185081
[No Abstract] [Full Text] [Related]
16. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
[TBL] [Abstract][Full Text] [Related]
17. Clinical evaluation of ftorafur (pyrimidine-deoxyribose n1-2'-furanidyl-5-fluorouracil).
Valdivieso M; Bodey GP; Gottlieb JA; Freireich EJ
Cancer Res; 1976 May; 36(5):1821-4. PubMed ID: 1268838
[TBL] [Abstract][Full Text] [Related]
18. [Effect of 5-fluorouracil on digestive tract cancer. Study and results of 18 cases].
Daccak M
Rev Med Moyen Orient; 1967; 24(2):155-9. PubMed ID: 5248419
[No Abstract] [Full Text] [Related]
19. [Results of treatment with 5-fluorouracil in 75 cases with neoplasms of the digestive tract].
Paolucci R
Policlinico Chir; 1971; 78(6):303-18. PubMed ID: 5146512
[No Abstract] [Full Text] [Related]
20. CANCER CHEMOTHERAPY OF THE GASTROINTESTINAL TRACT WITH REFERENCE TO INTRA-ARTERIAL INFUSION AND IRRADIATION.
LAWTON RL
Am J Surg; 1965 Jan; 109():47-51. PubMed ID: 14248296
[No Abstract] [Full Text] [Related]
[Next] [New Search]
